NEW YORK, Sept. 9, 2016 /PRNewswire/ -- Notice is hereby
given that Faruqi & Faruqi, LLP has filed a class action
lawsuit in the United States District Court for the Northern
District of California, case no.
3:16-cv-05154, on behalf of shareholders of Medivation, Inc.
("Medivation" or the "Company") (NasdaqGS:MDVN) who held
Medivation securities and have been harmed by Medivation's and its
board of directors' (the "Board") alleged violations of Sections
14(d)(4), 14(e), and 20(a) of the Securities Exchange Act of 1934
(the "Exchange Act") and SEC Rule 14d-9 in connection with the
proposed acquisition ("Proposed Transaction") of the Company by
Pfizer, Inc.(" Pfizer").
On August 30, 2016, Montreal, Inc., a wholly-owned subsidiary of
Pfizer, commenced a tender offer for Medivation shares scheduled to
expire on September 27, 2016. If a
sufficient number of Medivation shares are tendered, a second-step
merger will be effectuated without a shareholder vote, and
Montreal, Inc. will merge with and
into Medivation, with Medivation continuing as a wholly-owned
subsidiary of Pfizer.
If you wish to obtain information concerning this action or
view a copy of the complaint, you can do so by clicking here:
www.faruqilaw.com/MDVNnotice.
Pursuant to the terms of the Merger Agreement, which was
unanimously approved by the Board, Medivation shareholders stand to
receive $81.50 per share in cash for
each share they own. The complaint claims that this offer is
inadequate in light of the Company's intrinsic value and long-term
prospects and alleges that the Schedule 14D-9
Solicitation/Recommendation Statement (the "14D-9") provides
materially incomplete and misleading information about the process
leading up to the Board's decision to approve the Proposed
Transaction and the valuation analyses performed by the Board's
financial advisors, in violation of Sections 14(d)(4), 14(e), and
20(a) of the Exchange Act.
Take Action
Plaintiff is represented by Faruqi & Faruqi, LLP, a law firm
with extensive experience in prosecuting class actions, and
significant expertise in actions involving corporate fraud.
Faruqi & Faruqi, LLP, was founded in 1995 and the firm
maintains its principal office in New
York City, with offices in Delaware, California, and Pennsylvania.
If you wish to serve as lead plaintiff, you must move the Court
no later than 60 days from today. Any member of the putative
class may move the Court to serve as lead plaintiff through counsel
of their choice, or may choose to do nothing and remain an absent
class member. If you wish to discuss this action, or have any
questions concerning this notice or your rights or interests,
please contact:
Nadeem Faruqi, Esq.
James M. Wilson, Jr., Esq.
FARUQI & FARUQI, LLP
685 3rd Avenue, 26th Floor
New York, NY 10017
Tel.: (212) 983-9330
Fax: (212) 983-9331
E-mail: nfaruqi@faruqilaw.com
jwilson@faruqilaw.com
Logo -
http://photos.prnewswire.com/prnh/20120119/MM38856LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/faruqi--faruqi-llp-announces-filing-of-a-class-action-lawsuit-against-medivation-inc-300325623.html
SOURCE Faruqi & Faruqi, LLP